Overview

  • Product name
  • Description
    Mouse monoclonal to DPD
  • Host species
    Mouse
  • Tested applications
    Suitable for: WB, ICC/IF, IHC-P, Flow Cytmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant fragment corresponding to Human DPD aa 1-111.

Properties

Applications

Our Abpromise guarantee covers the use of ab54797 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 - 5 µg/ml. Predicted molecular weight: 111 kDa.
ICC/IF Use a concentration of 10 µg/ml.
IHC-P 1/100.
Flow Cyt Use 1µg for 106 cells.

ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.

 

Target

  • Function
    Involved in pyrimidine base degradation. Catalyzes the reduction of uracil and thymine. Also involved the degradation of the chemotherapeutic drug 5-fluorouracil.
  • Tissue specificity
    Found in most tissues with greatest activity found in liver and peripheral blood mononuclear cells.
  • Pathway
    Amino-acid biosynthesis; beta-alanine biosynthesis.
  • Involvement in disease
    Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) [MIM:274270]; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.
  • Sequence similarities
    Belongs to the dihydropyrimidine dehydrogenase family.
    Contains 3 4Fe-4S ferredoxin-type domains.
  • Cellular localization
    Cytoplasm.
  • Information by UniProt
  • Database links
  • Alternative names
    • DHP antibody
    • DHPDHase antibody
    • Dihydropyrimidine dehydrogenase [NADP(+)] antibody
    • Dihydropyrimidine dehydrogenase [NADP+] antibody
    • Dihydropyrimidine dehydrogenase antibody
    • Dihydrothymine dehydrogenase antibody
    • Dihydrouracil dehydrogenase antibody
    • DPD antibody
    • DPYD antibody
    • DPYD_HUMAN antibody
    • MGC132008 antibody
    • MGC70799 antibody
    • OTTHUMP00000058954 antibody
    see all

Images

  • DPD antibody (ab54797) at 1ug/lane + HeLa cell lysate at 25ug/lane.

  • ab54797 at 10 ug/ml staining DPD in human Hela cells by Immunocytochemistry / Immunofluorescence.

  • Overlay histogram showing HepG2 cells stained with ab54797 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab54797, 1µg/1x106 cells) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in HepG2 cells fixed with 100% methanol (5 min)/permeabilized in 0.1% PBS-Tween used under the same conditions.

References

This product has been referenced in:
  • Qin F  et al. Effect of dihydropyrimidine dehydrogenase single nucleotide polymorphisms on prognosis of breast cancer patients with chemotherapy. Oncotarget 8:112060-112075 (2017). Read more (PubMed: 29340111) »
  • Wu R  et al. Histone H3K27 Trimethylation Modulates 5-Fluorouracil Resistance by Inhibiting PU.1 Binding to the DPYD Promoter. Cancer Res 76:6362-6373 (2016). WB . Read more (PubMed: 27578004) »
See all 7 Publications for this product

Customer reviews and Q&As

1-2 of 2 Abreviews or Q&A

Answer

Thank you for confirming these details and for your cooperation. The details provided enable us to closely monitor the quality of our products.

I am sorry this product did not perform as stated on the datasheet and for the inconvenience this has caused. As requested, I have issued a free of charge replacement with a different lot number. This is on the order number xxxxx. Before shipping it may be consolidated to a different order. Please quote "FOCR CCExxxxxx" if discussing the delivery with our customer service representatives.

I would like to point out that theantibody was outside ofthe warrantyperiod covered by theAbpromise by 1 month (purchased on the 1st ofDecember 2011). I have issued thisfree of charge replacement as a gesture ofgoodwill. In the futureI would stronglysuggest to your customer that they report any problems encountered as soon as possible. This way we can hopefullybe of more help to them.

Please note that this free of charge replacement vial is also covered by our Abpromise guarantee. Should you still be experiencing difficulties, or if you have any further questions, please do not hesitate to let us know.

I look forward to hearing how your customer gets on with the new vial.

Read More

Answer

Thank you for taking time to complete our questionnaire. I am sorry to hear that this antibodyhas not providing satisfactory results. The details provided will enable us to investigate this case and will provide us with vital information for monitoring product quality.

Having reviewed this case, it is clear that the second lot tried by the customer has produced much higher background. I'd like to ask a few further questions in order to understand why this may be happening.

1. Was the exposure used with the new lot longer? The blot seems quite over exposed. Was there any trace of the expected band at lower exposure levels?

2. Was the secondary antibody used of the same lot as that used with the original lot of ab54797? Has a "no primary" control been performed in order to assess if the secondary antibody may be contributing to the background observed? Has this secondary been used successfully with other primary antibodies?

3. Was the same blocking agent used in the first blot? The blocking used is quite high and I would suggest cleaner results may be produced if 3% BSA is used (with 1% BSA in the antibody diluents) as well as introducing0.1%detergent into thediluent buffersas well as wash buffersto improve the level of non-specific binding seen.

In the event that a product is not functioning in the species and applications cited on the product datasheet (and the problem has been reported within 6 months of purchase), we would be pleased to provide a free of charge replacement, credit note, or refund.In order to organise thisI will need the original order numberunder which ab54797 was purchased.

I hope this information is helpful, and I thank you for your cooperation.

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up